ISouth Africa Delivery, iDaily Domestic Delivery, I-European Domestic Delivery

Alprostadil, (PGE1), iProstaglandin E1

Akukho kalo
5.00 ngaphandle kwe 5 ngenxa ye 1 ireyithingi abathengi
SKU: 745-65-3. Udidi:

AASraw unani kuyondelelaniswe kunye nemveliso nako ukusuka gram ukuya zesininzi Alprostadil, (PGE1), Prostaglandin E1 (745-65-3), phantsi komqathango CGMP kunye nenkqubo yolawulo lomgangatho zibonwe.

Iprostaglandin i-E1 (PGE1), eyaziwa nangokuthi i-alprostadil, i-prostaglandin eyenziwa ngokwemvelo esetyenziswa njengamayeza. Kwiintsana ezinokukhubazeka kwentliziyo yesisu, isetyenziselwa i-injection ephuculayo kwisiswini sokuvula i-ductus arteriosus de kube yinto yokuhlinzwa. Ngokujola kwi-penis okanye ukubekwa kwi-urethra, isetyenziselwa ukuphathwa kakubi kwe-erectile.

I-AASRAW powder PDF Icon

Ingcaciso yeMveliso

Alprostadil, (PGE1), iProstaglandin Ividiyo ye-E1


Alprostadil, (PGE1), i-Prostaglandin i-E1 Abalinganiswa basisiseko

igama: Alprostadil, (PGE1), iProstaglandin E1
CAS: 745-65-3
I-molecular Formula: C20H34O5
Isisindo somzimba: 354.48
Melt Point: 115-116 ° C
Isitoreji sokugcina: 2 ° -8 ° C
umbala: Powder


I-Alprostadil, (PGE1), i-Prostaglandin E1 (745-65-3) ekusebenziseni umjikelezo we-steroids

Amagama

Alprostadil, (PGE1), i-Prostaglandin i-E1 (i-CAS 745-65-3), ebizwa ngokuba nguAvastin noMvasi.

Alprostadil, (PGE1), Prostaglandin I-E1 Ukusetyenziswa

I-Bevacizumab iza njengesisombululo sokuphatha ngokukhawuleza kwisithambiso. I-Bevacizumab ilawulwa ngugqirha okanye umongikazi kwiofisi yezokwelapha, isikhungo sokungena ngaphakathi, okanye esibhedlele. I-Bevacizumab ivame ukunikezwa kanye emva kweeyure ze-2 okanye ze-3.

Kufuneka kuthathe imizuzu ye-90 ukuba ufumane umthamo wakho wokuqala we-bevacizumab. Ugqirha okanye umongikazi uyakukujonga ngokukhawuleza ukuba ubone indlela umzimba wakho uphatha ngayo kwi-bevacizumab. Ukuba ungenayo ingxaki enzulu xa ufumana i-dose yokuqala ye-bevacizumab, ngokuqhelekileyo kuthatha i-30 kwimigqa ye-60 ukuba ufumane ngalinye lezilwanyana zakho eziseleyo.

Inyolo yeBevacizumab ingabangela ukuphendula okukhulu ngexesha lokunyuka kwamachiza. Ukuba ufumana enye yeempawu ezilandelayo, xela ugqirha wakho ngokukhawuleza: ukuphefumula ukuphefumula okanye ukuphefumula, ukugubha, ukuthuthumela, ukujuluka, intloko, isifuba, ukuxakeka, ukuxakeka, ukuxubha, ukugubha, okanye ukuvuthwa. Ugqirha wakho unokufuna ukunciphisa ukunyuswa kwakho, okanye ukulibaziseka okanye ukuyeka unyango lwakho xa ufumana ezi okanye ezinye iziphumo.

Indlela uAlprostadil, (PGE1), iProstaglandin E1 (745-65-3) isebenza ngayo

Ukuze unyango lwe-erectile dysfunction (ED), i-alprostadil ibuyisela kwakhona imisipha evulekileyo ye-corpus cavernosum; nangona kunjalo, akukho ndlela ekhoyo yokusebenza. Kubonakala ukuba iziphumo zibangelwa ukwandisa i-intracellular concentrations ye-AMP ye-cyclic. U-Alprostadil udibanisa kunye nama-receptors athile adibeneyo okukhuthaza i-adenylate cyclase nokuphakamisa i-intracellular cyclic AMP, ekhokelela ekusebenziseni iprotheni kinase kunye nokuphumla kwe-muscle ehamba phambili. Le nyathelo ihluke kwi-papaverine evimbela i-phosphorylation ene-oxidative ye-oxidative ye-AMP kwaye iphazamise ukuhlanganiswa kwe-calcium ngexesha lokuqhekeka kwemisipha. Alprostadil kwakhona ukumcaphukisa izenzo vasoconstrictive of norepinephrine ngokuthintela ukukhululwa neuronal of norepinephrine kwaye yandise izenzo nonadrenergic, neurotransmitters noncholinergic vasodilatory. Ekuphatheni i-ED, i-alprostadil ikhuthaza ukulungiswa ngokuzikhumuza izihlunu ezinobungozi kunye nokuxubusha imitha ye-cavernosal kunye namasebe awo. Ukuxilwa kweempawu ze-cavernosal kuhambelana nokunyuka kwe-asclow inflow velocity kunye nokunyuka kwe-outflow. Ngenxa yoko, izithuba ze-lacunar zandisa kwaye igazi liye lathinteka kwinqanaba elincinci lokunyanzeliswa kwama-venules ngokumelene ne-tunica albuginea. Ukufezekisa i-tumescence ne-rigidity efanelekileyo, i-tunica albuginea kufuneka iyanelisekile ngokwaneleyo ukunyanzelisa i-venules ingena ngaphakathi kwaye ikhusele ukuphuma kwe-venous. Le nkqubo iphinda ibhekiswe njengendlela ye-veno-occlusive mechanical. I-Alprostadil ayithinteli ngqo kwi-ejaculation okanye i-orgasm.

Xa unyango lwe-ductus arteriosus oluxhomekeke kwimpembelelo yesifo senhliziyo, i-alprostadil igcina i-ductal patency ngokuphucula imisipha evulekileyo ye-ductus arteriosus. U-Alprostadil uyasebenza kuphela xa unikezelwa phambi kokuvala i-anatomic yokuvalwa kwe-ductus arteriosus. Ulawulo alprostadil ukuya neonates kunye cyanotic iziphene ngentliziyo naso (imiqathango pulmonary flow igazi) iziphumo ukwanda kwemali yemiphunga kwegazi kunye / okanye ukwanda ukuxubana phakathi kwegazi miphungeni ekhokelela ukunyuselwa okwexeshana lwemithambo oksijini ingcinezelo buso (PaO2) kunye ne-oxygen saturation. Impendulo ye-cyanotic neonate kwi-alprostadil yonyango iphinda ihambelane nokuxhatshazwa kwe-PO2. Impendulo enkulu kunazo zonke ivela kwii-neonates ezine-PO2 (<20 torr), ezincinci i-ductus arteriosus, kunye neentsuku ze-4 ubudala okanye ezincinci. I-Neonates namaxabiso e-PaO2 we-40 torr okanye ngaphezulu ayinayo impendulo encinane kwi-alprostadil.

Xa neonates nge enomda ukuhamba kwegazi lwenkqubo, ulawulo alprostadil kunokubangela nokuthintela okanye ukulungiswa acidemia, kunyuke imveliso kwentliziyo nokonyuka systemic uxinzelelo lwegazi, yobungakanani ukubetha femoral, ekwandeni kokuqukuqela igazi kwezintso kunye nomsebenzi, sinciphise ithambeka kwehlela ngokunyuka ingcinezelo igazi aortic (kwi-neonates kunye ne-coarctation ye-aorta), kunye / okanye ukunciphisa umlinganiselo woxinzelelo lwe-pulmonary umthamo wokuhla kwe-aortic (kwi-neonates kunye nokuphazanyiswa kwe-artic arch). Ngokungafaniyo ne-cyanotic neonates, ukuphumelela kwe-alprostadil kwi-acyanotic neonates ayixhomekeke kwiminyaka yobudala okanye i-PaO2 yobudala.

I mi yalelo

I-Alprostadil (i-Prostglandin E1) isetyenziselwa ukuphatha i-erectile disys function (ED) kumadoda amakhulu. Ukusebenza kwe-alprostadil ekuphatheni i-ED ihambelana nesizathu; Izinga lokuphendula lisoloko liphantsi kwizigulane ezine-ED ngenxa yezinto ezixubekileyo zezobugcisa ezifaniswa nalabo abane-ED ngenxa ye-neurogenic, ye-psychogenic, okanye i-vasculogenic. Ifomu ezimbini zithengiswa ekuphatheni i-ED: umkhiqizo we-transurethral (Muse) osebenzisa i-pellet edibeneyo elawulwa kwi-urethra kunye nejoza (Caverject okanye Edex) ejoyiweyo ngqo kwi-corpus cavernosa. Amanye amafayili e-dosage afana ne-gel yenkcazo kunye nenkqubo yokuhambisa i-liposomal engekho intsha iphantsi kophando. Ngokwezikhokelo zonyango lwe-ED, uhlobo lwe-phosphodiesterase yomlomo lwe-5 inhibitors (PDE5 inhibitor) lubonwa ngonyango lokuqala. Izinketho zonyango lweyesibili zibandakanya i-intracavernous injection kunye ne-intra-urethra. Ukwelashwa kwe-Intracavernous yonyango yonyango olusebenzayo olungapheliyo lwe-ED, ngokuphendula kwangaphambili nokuqhubekayo. Nangona kunjalo, ingabonakaliswa kwaye iyabonakalisa imiphumo emibi echaphazelekayo kubandakanywa ukuxhamla kunye ne-penile fibrosis. Iziqinisekiso ze-FDA zilandelayo: I-Caverject ngoJulayi 1995, i-MUSE ngo-Oktobha 1996, kunye ne-Edex ngoJuni 1997.

I-Alprostadil kunye nezinye i-prostaglandines kwii-E series ziqhelekile kwi-placenta kunye ne-ductus arteriosus ye-fetus. I-type ye-E-prostaglandins i-arasooles i-vasodilate ngokuphumla ngokuthe ngqo kwe-muscular smooth muscle. Okunye Iziphumo pharmacologic ziquka ukwanda kwimveliso kwentliziyo, komlomo zombini iimpahla systemic miphungeni, komlomo le arteriosus ductus, inhibition of zegazi ukulinganiswa, ukunyenyisa okuthile izihlunu inyumoniya, ukwanda kwemali egazini sezintso, kunye nokubambezeleka of esiswini ixesha ingabi nanto. Intravenous alprostadil isetyenziselwa i-neonates kunye nokuphazamiseka kwe-ventricular outflow ukugcina ubuchule be-ductus arteriosus kude kube nexesha lokulungiswa okanye ukuhlinzwa ngokugqithiseleyo. U-Alprostadil usebenza ngokubanzi kulawo ma-neonates anegazi eliphantsi lokuxhatshazwa kwegazi PO2 kunye nabani na iintsuku ze-4 ubudala okanye ngaphantsi. Kwiintsuku ezidlulileyo kuneentsuku ze-4, kukho ukuhla kwe-reacal muscle reactivity ngenxa yokutshintsha kwexesha lokuzalwa emva kokuzalwa kwidonga ye-ductus arteriosus. I-alprostadil engenakudinga idinga ukunyamekela ukuphefumula ngexesha lolawulo kuba i-apnea ikhula kwi-10-12% yeenonates. I-Alprostadil i-FDA ivunyiwe kwizigulane zezilwanyana njengabancinci. Iprostin VR I-Pediatric ivunyiwe yi-FDA kwi-1981.


Indlela yokuthenga i-Alprostadil, (PGE1), iProstaglandin E1 esuka kwi-AASraw

1.Qhagamshelana nathi nge-imeyile yethu inkqubo yophando, okanye i-skype ye-intanethiummeli wenkonzo yamakhasimende (CSR).
2.Ukusibonelela ngobuninzi bakho kunye neadesi.
I-3.I-CSR yethu iya kukunika isingeniso, ixesha lokuhlawula, inombolo yokulandelela, iindlela zokuhambisa kunye nomhla wokufika oqikelelwayo (i-ETA).
I-4.Inkokhelo eyenziwe kwaye iimpahla ziya kuthunyelwa kwiiyure ze-12 (Ukuze ulandelwe ngaphakathi kwe-10kg).
5.Goods zifunyenwe kwaye zinike izimvo.


=

IAAA

HNMR

Recipes

Iziqulatho kunye nokuqulunqwa kwemveliso

ngokutsha 1 ngenxa Alprostadil, (PGE1), iProstaglandin E1

  1. ikaliwe 5 ngaphandle 5

    Aasraw -

    Alprostadil, (PGE1), iProstaglandin i-E1 powder iyinhlakanipho

Yongeza kwakhona

Idilesi yakho ye email aziyi kupapashwa. amasimi ezifunekayo ziphawulwa *